Avalo Therapeutics share#snapshot#suffix 131885077 / US05338F3064
13.65
USD
0.23
USD
1.68 %
09.10.2026
BTT
| prices + charts + realtime | news + analysis | fundamental | company | corresponding shares | action | |
|---|---|---|---|---|---|---|
| price + Chart | chart (large) | news + ad-hoc | balance sheet/p&l | fixed dates | certificates | portfolio#add_instrument_to#depot |
| times + sale | chart comparison | analysis | detailnavigation#shares#estimates | profile | portfolio#add_instrument_to#watchlist | |
| stock exchange | realtime push | stock price appreciation potential | dividend/annual shareholders' meeting | |||
| historic | analysis | |||||
prices + charts + realtime
news + analysis
fundamental
company
corresponding shares
Aktie Analysen & Prognosen
Fundamentalanalyse
| Preis | Mrk. Kap. in Mrd. $ | revid. Gew. Prognose | Bewertung | Wachstum / KGV | KGV 2020 | langfrist. Wachstum | Div. Rend. | mittelfrist. Mkt Trend | rel. 4 Wo. Perform. |
|---|---|---|---|---|---|---|---|---|---|
| 13.65 USD | % | % | % |
| revid. Gewinn Prognose | ||||
| Bewertung | ||||
| relative 4 Wochen Performance | % | |||
| mittelfristiger Markttrend | ||||
| Markt Kapitalisierung in Mrd. $ | Grosser Marktwert | Mit einer Marktkapitalisierung von > $5 Mrd., ist ein hoch kapitalisierter Titel. | ||
| Wachstum / KGV | ||||
| KGV | ||||
| langfristiges Wachstum | % | Wachstum heute bis p.a. | Die durschnittlichen jährlichen Wachstumsraten gelten für die Gewinne von heute bis | |
| Anzahl der Analysten | Nur von wenigen Analysten verfolgt | In den zuräckliegenden sieben Wochen haben durchschnittlich Analysten eine Schätzung des Gewinns pro Aktie für diesen Titel abgegeben. | ||
| Dividenden Rendite | % | |||
| Zeichenerklärung | ||
|---|---|---|
| revidierte Gewinn Prognose | = , | = , |
| Bewertung | = , | = , , |
| relative 4 Wochen Performance | = negative Werte | = positive Werte |
| mittelfristiger Markttrend | = , | = , |
Risikoanalyse
| Preis | Mrk. Kap. in Mrd. $ | Bear Market Faktor | Bad News Faktor | Beta 1 Jahr | Korrelation |
|---|---|---|---|---|---|
| 13.65 USD |
| Risiko | |||
| Bear Market | |||
| Bad News | |||
| Beta | Die Aktie tendiert dazu, pro 1% Indexbewegung mit einem Ausschlag von % zu reagieren. | ||
| Korrelation 365 Tage | |||
shares#estimates#headline Avalo Therapeutics in USD
| 2026 | 2027 | 2028 | 2029 | 2030 | |
|---|---|---|---|---|---|
| shares#estimates#column#sales | 0.00 | 0.00 | 0.00 | 0.00 | 119.49 |
| shares#estimates#column#dividendspershare | 0.01 | 0.00 | |||
| shares#estimates#column#dividendyield | 0.08 % | 0.01 % | % | % | % |
| shares#estimates#column#earningpersharebasic | -2.92 | -2.98 | -3.34 | -3.69 | -2.31 |
| shares#estimates#column#pricetoearningsratio | -4.68 | -4.58 | -4.08 | -3.70 | -5.90 |
| shares#estimates#column#earningsbeforeinterestandtaxes | -109.38 | -139.24 | -180.73 | -218.68 | -162.96 |
| shares#estimates#column#earningsbeforeinteresttaxesdepreciationamortization | -96.92 | -132.73 | |||
| shares#estimates#column#netprofit | -110.34 | -136.72 | -185.03 | -222.37 | -168.84 |
| shares#estimates#column#netprofitadjusted | -103.42 | -139.87 | |||
| shares#estimates#column#pretaxprofit | -113.08 | -141.49 | -185.03 | -222.37 | -168.51 |
| shares#estimates#column#pretaxprofitreported | |||||
| shares#estimates#column#earningpersharenongaap | -3.11 | -3.69 | -4.95 | -4.99 | 0.34 |
| shares#estimates#column#earningpersharereported | -3.01 | -2.72 | -3.22 | -3.32 | -1.41 |
| shares#estimates#column#grossincome | 0.00 | 0.00 | 0.00 | 0.00 | 25.80 |
| shares#estimates#column#cashflowfrominvesting | -0.50 | ||||
| shares#estimates#column#cashflowfromoperations | -82.00 | -112.60 | |||
| shares#estimates#column#cashflowfromfinancing | 405.40 | ||||
| shares#estimates#column#cashflowpershare | 0.00 | 0.00 | |||
| shares#estimates#column#freecashflow | |||||
| shares#estimates#column#freecashflowpershare | |||||
| shares#estimates#column#bookvaluepershare | |||||
| shares#estimates#column#netdebt | -424.00 | -305.55 | -426.80 | -445.30 | -413.00 |
| shares#estimates#column#researchanddevelopment | 78.49 | 102.17 | 139.54 | 164.73 | 176.76 |
| shares#estimates#column#capitalexpenditure | 0.50 | ||||
| shares#estimates#column#sellinggeneralandadministrativeexpense | 31.48 | 36.84 | 42.92 | 57.94 | 112.49 |
| shares#estimates#column#shareholdersequity | |||||
| shares#estimates#column#totalassets |
shares#estimates#footer
Avalo Therapeutics Inc Registered Shs Aktie Analysen
error#message#nodata